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The viability and subtle developmental defects of p53 knockout mice suggest that p53 does not play major role in
development. However, contradictory evidence also exists. This discrepancy mainly results from the lack of
molecular and cellular mechanisms and the general fact that p53 activation requires stresses. Recent studies of p53
in mouse and human ES cells and induced pluripotent stem (iPS) cells shed new light on the mechanisms of the
developmental roles of p53. This review summarizes these new studies that support the developmental roles of
p53, highlights the possible underlying molecular mechanisms, and discusses the potential relationship between
the developmental roles and the tumor suppressive function of p53. In summary, the molecular mechanisms
underlying the developmental roles of p53 are emerging, and the developmental roles and tumor suppressive
function of p53 may be closely related.
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When it was first discovered as a SV40 binding protein,
it was believed to be an oncoprotein because it is highly
expressed in many types of tumors and the p53 cDNA
from these tumors can transform normal cells together
with H-Ras [1-6]. Later on, studies by several laborator-
ies convincingly showed that wild type p53 is a tumor
suppressor [7-9]. Because the mutation of the p53 gene
occurs in more than half of human tumors, all of the
earlier cloned p53 cDNAs from these tumor cells had
mutations that either disrupted the activity of p53 or
made p53 oncogenic. Soon afterwards, p53 mutants
were found to have gain-of-functions, which explain
some oncogenic phenotypes of mutated p53 cDNAs
[10]. Therefore, a single amino acid change of p53 could
switch it from a tumor suppressor to an oncogene. Simi-
lar to these studies in tumor cells, the studies of the
developmental roles of p53 have also generated puz-
zling, sometimes contradictory, data. The absence of
obvious developmental defects in p53 knockout mice
strongly suggests that p53 is not required for develop-
ment [11]. Other studies, however, suggest that p53,* Correspondence: huangj3@mail.nih.gov
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reproduction in any medium, provided the orunder certain conditions, is involved in the development
of mice [12,13]. In Xenopus, p53 loss causes developmen-
tal defects by interacting with TGF beta signaling [14-16].
Recent studies using embryonic stem cells as a model sys-
tem to study the function of p53 provided interesting in-
sights into the developmental roles of p53. This review
will highlight these new studies and re-visit the possible
models of p53 in development.The potential roles of p53 in development
p53 is involved in normal organogenesis
Given that p53 is important and highly expressed during
development, it was surprising to observe that p53
knockout mice developed normally, while the adult mice
quickly developed tumors [11]. Since then, it had been
believed that p53 does not play a role during develop-
ment. Subsequent studies by two independent groups
revealed that p53 null mice are subject to subtle devel-
opmental defects with exencephaly being one of the
major developmental defects and, to a lesser degree,
craniofacial malformations [12,13]. These developmen-
tal defects are dependent on the genetic background
and gender. Mice with 129/Sv background and females
are more affected by p53 loss than C57BL/B6 and male
mice. The exencephaly penetrance is about 23% in the
females of 129/Sv strain. These results suggest a subtled. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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p53 loss affects females more than males and why the
penetrance of developmental defects is low. The pos-
sible roles of p53 in neuronal development have been
thoroughly discussed in another review article [17].
Another organ that has obvious defects in p53 knock-
out mice is the testis [18]. The testes from p53 knockout
mice contain multinucleated cells resulting from primary
spermatocytes that fail to undergo meiosis [18]. How-
ever, this spermatogenesis defect is observed in adult
mice, and it is unknown whether the abnormality initi-
ates from the embryonic stage. Mice with a 129 genetic
background are more susceptible to spermatogenesis de-
fects. This observation is coincident with the fact that
129 mice with p53 knockout develop teratomas at a high
frequency and are sterile. But more studies are needed
to establish a firm connection between the roles of p53
in spermatogenesis and teratoma suppression. Recently,
p53 has been shown to play a role in kidney development
through activating the expression of Pax2, a critical tran-
scription factor for kidney development [19] (Table 1). In-
triguingly, Pax2 inhibits the activity of p53. Therefore, this
mutual regulation forms a negative feedback loop during
nephrogenesis [19]. Through genome-wide analysis, the
kidney developmental pathways have been linked to clear
cell renal cell carcinoma (ccRCC) [20]. Therefore, future
studies need to address whether the p53/Pax2 axis is in-
volved in the initiation or progression of ccRCC.
Embryonic lethality regulated by p53 in response
to stresses
The most direct evidence showing that p53 is able to
affect development is from the study of mdm2 knockout
mice. Mdm2 knockout mice die between implantation
and E5.5, around the stage of blastocysts from which
embryonic stem cells are derived [21,22]. In addition,
crossing Mdm2 knockout mice with p53 knockout mice
completely rescued the lethal phenotype. Because ESTable 1 Developmental and reproductive anomalies associate
Anomalies Stage Stress Background
Implantation
failure
Pre-implantation Physiological C57BL/6 J (more se
129/Sv and Mix
Exencephaly Embryonic Physiological 129 (more severe),




Tail anomaly Fetuses X-ray 129/SvJ
Muscle Adult Physiological Unknown
Testis Adult Physiological 129 (100% penetran
C57BL/6X129 mix
background is normcells are derived from blastocysts, these results provide
strong biological evidence that p53 can be activated at
the ES cell stage. During normal development, its activ-
ity is kept in check by Mdm2 and its homologue Mdm4
(also called MdmX). Interestingly, Mdm4 null mice die
around 7.5-8.5 d.p.c. (days post coitum), suggesting that
Mdm4 and Mdm2 play non-redundant roles during early
development. The lethal phenotypes of both Mdm2 and
Mdm4 knockout mice can be completely rescued by p53
null mice, demonstrating that p53 is involved in the devel-
opmental lethality of Mdm2 and Mdm4 knockout mice.
Similar rescue and partial rescue phenotypes were ob-
served in mES cells, blastocysts, or mice with knockouts
of other genes, such as Brca1 [23-25], Brca2 [26], Rad51
[27], Cdc7 [28], Pict1 [29], L11 [30], Aurora kinase A [31],
or Tsg101 [32]. Most of these genes are involved in DNA
repair, cell cycle regulation, and nucleolar stress. These
studies demonstrate that p53 can have developmental
roles when the dysregulation of certain genes causes DNA
damage, ribosomal stress, or other un-identified stresses.
p53 regulates embryo implantation
p53 also can influence mouse embryo implantation by
regulating the maternal Lif levels [33] (Table 1). Lif is an
important maternal factor that facilitates embryo im-
plantation. Loss of p53 in female mice greatly decreases
the number of implanted embryos. This may represent
one of the ways to decrease the reproductive ability of
females with p53 defects. As mentioned above, p53 de-
fects also cause abnormal spermatogenesis in mice [18].
Therefore, it is reasonable to speculate that loss of p53
and other p53 family members, p63 and p73, will even-
tually lead to reproductive disadvantage [34]. Indeed,
the roles of p63 and p73 in reproduction have been
reported [35,36]. Interestingly, the effect of p53 loss on
embryo implantation is more severe in C57BL/6 J
background, while the effect on spermatogenesis is




vere), p53 regulates Lif Hu, et al., Nature, 2007
C57BL/6 Unclear Armstrong, et al., Curr. Biol., 1995;
Sah, et al., Nature Genetics, 1995
p53 regulates Pax2 Saifudeen, et al., Plos One, 2012
Unclear Norimura, et al., Nature Medicine, 1996
Unclear Norimura, et al., Nature Medicine, 1996
Unclear Molchadsky, et al., Plos One, 2008
ce),
al
Unclear Rotter, et al., PNAS, 1993
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effect of p53 loss on implantation [18].
p53 regulates teratogenesis in mice
An interesting study showed that p53 dependent apop-
tosis may be involved in X irradiation-induced terato-
genesis [37]. In this study, X irradiation was used to
treat implanted embryos at day 3.5 of gestation. 73% of
p53+/+ embryos had early death, while 27% survived
and displayed normal development. In contrast, only
44% of p53-/- embryos died early, 30% died late, 22%
had developmental anomalies, and only 4% developed
normally. These results indicate that p53-dependent
apoptosis antagonizes teratogenesis by inducing embry-
onic death and involving an un-characterized “repairing”
mechanism.
Molecular and cellular mechanisms of the
developmental roles of p53
The potential developmental roles of p53 have been ex-
tensively covered in another review article [38,39]. How-
ever, the molecular and cellular mechanisms of are not
well characterized. Due to the introduction of novel
technologies, such as genome-wide approaches, recent
studies of p53 in ES cells shed some new light on this
old topic [40,41]. In addition to its role in ES cells, p53
also has functions in other adult stem cells, such as
muscle cell progenitors and osteoprogenitors [42,43].
The activity and levels of p53 in early embryos are
higher than those in late embryos [44-46]. In vitro, the
levels of p53 in ES cells decreases as ES cells differenti-
ate [47]. Because ES cells are derived from blastocysts,
they represent an excellent model system to study the
early developmental role of p53 [48].
p53 is kept in check by Mdm2, Mdm4 and delta40-p53
Without stresses, the high levels of p53 do not lead to
the apoptosis or differentiation of ES cells because its ac-
tivity is inhibited by Mdm2 and Mdm4 [49]. Removal of
Mdm2 causes cell death at the blastocyst stage, indicat-
ing that p53 is poised for activation at the ES cell stage.
Interestingly, deletion of Mdm4 leads to embryonic
death at a later developmental stage. But it is possible
that Mdm4 plays a cooperative role with Mdm2. A re-
cent study suggests that Mdm4 has a function in ES
cells [49].
Delta40-p53 is a naturally occurring splicing variant of
p53, with an amino terminal deletion of 40 amino acids
[50]. Delta40-p53 is highly expressed in ES cells and in-
hibits p53-dependent transcriptional activity. In addition,
delta40-p53 appears to affect the Insulin Growth factor
1 receptor (IGF-1R) signaling, which has been shown to
participate in the differentiation program of ES cells. It
is currently unknown whether Delta40-p53 cooperateswith Mdm2 and/or Mdm4 to suppress the activity of
p53. It is likely that multiple distinct mechanisms exist
in ES cells and embryos to maintain low activity of p53.
p53 can be activated in ES cell stage under certain
conditions, such as Brca1 deletion. Brca1 is a protein
that is involved in repairing DNA double strand breaks
through homologous recombination. Its deletion in ES
cells activates p53, causing the differentiation and/or
apoptosis of ES cells. Therefore, ES cells containing
Brca1 deletion are not viable [23,51] (Figure 1). The re-
duction of p53 levels in ES cells by short hairpin RNA
(shRNA) can rescue the lethality caused by Brca1 loss,
demonstrating that p53 activation is downstream of
Brca1 loss. Similar results were observed in the Aurora
kinase-p53 axis in mES cells [31].
Functional outcomes of p53 activation in ES cells
Although it is clear that p53 induces apoptosis in human
embryonic stem cells (hESCs) in response to DNA dam-
age [52,53], it is controversial whether p53 can induce
apoptosis in mES cells. Some studies showed that p53 is
sequestered in the cytoplasm of mES cells, and that mES
cells undergo p53-independent apoptosis in response to
DNA damage [54]. Others have found that mES cells
undergo p53-dependent apoptosis [55]. Different batches
of sera, media, and the heterogeneity of ES cell culture
could potentially explain this discrepancy.
Despite the controversy of the apoptotic function of
p53, the differentiation regulation is a well-established
function of p53 in mES cells. Upon DNA damage, p53
induces the differentiation of mES cells by repressing
the transcription of Nanog (Figure 2A) [56]. Apart from
its pro-differentiation activity, p53 also induces the tran-
scription of many Wnt ligand genes upon DNA damage
to delay the differentiation of neighboring cells (Figure 2A)
[57]. However, in differentiated cells (e.g. mouse embry-
onic fibroblasts) and neural progenitor cells, the induction
of Wnt ligands by p53 is greatly attenuated, suggesting
that the p53/Wnt axis may play a unique role in ES
cells. It is possible that the p53/Wnt axis acts as a
compensatory or “repairing” mechanism to restore the
ES cell population [58].
It is emerging that p53 is fully functional in mES cells
in response to DNA damage stress. In mES cells, p53
seems to play an important function by regulating the
development-associated genes because these genes are
more enriched in p53-regulated genes than apoptosis-
and cell cycle-associated genes [31,40]. This observation
probably represents the fact that ES cells are derived
from an early developmental stage. As a well character-
ized cellular state, ES cells serve as a good model system
for studying the early developmental events of p53 sig-
naling. It is noteworthy that the roles of p53 in develop-






































Figure 1 The roles of p53 in ES cells and blastocysts. A, Mouse ES cells (in vitro) are derived from blastocysts (in vivo) at embryonic day 3.5.
B, In the absence of stress, p53 is inactive in ES cells. But it can be activated by exogenous or endogenous stresses, such as DNA damage, in mES
cells. For example, the loss of Brca1 causes endogenous DNA damage stress, which in turn activates p53 to elicit differentiation and apoptosis of
mES cells. C, A hypomorphic Brca1 mutant causes DNA damage in blastocysts. When p53 is intact, the DNA damage signal will activate p53 and
cause the death of the blastocyst. Therefore, the developmental process is canceled. When the p53 surveillance system fails, the developmental
process goes on, while the female mice develop mammary gland tumors in adulthood.
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mental stages could affect the p53 signaling as well.
Technical advances of isolating pure populations from
early embryos will enable the analysis of p53 activity at
different lineages in the future.
The convergence of ES cell differentiation signaling and
p53-mediated stress signaling
One of the surprising findings about the molecular
mechanisms of p53 during development is that the p53
stress signaling and the developmental signaling merge
at their downstream gene level [59]. Upon DNA damage,
p53, like the differentiation cues during development, acti-
vates differentiation-associated genes while repressing
self-renewal genes in ES cells [59]. Interestingly, in mES
cells p53 is able to regulate gene transcription through
binding to the enhancers far from the gene body [59]. Thisopens up a new avenue to study the transcriptional regula-
tion, particularly repression, by p53. In mES cells, in re-
sponse to DNA damage, p53 represses the transcription of
many master regulators [59]. Surprisingly, p53 does not
bind to the promoter of these master regulators. Instead,
p53 binds to the distal regions to interfere with the enhan-
cer activity. It is worth noting that the interference of
enhancer is only one of the mechanisms underlying
the p53-mediated repression. p53 uses many different
ways to repress gene transcription in different cell
types, although most of these mechanisms involve the
promoter binding of p53 [60-63]. In human cells, p53
has also been shown to bind to the enhancers of
development- and environment-associated genes [64].
However, it is unknown whether the binding of p53 to the
enhancers in these human cells influences the transcrip-
tion. The precise mechanism of how p53 interferes with
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Figure 2 Molecular mechanisms underlying the roles of p53 in ES cells and iPS cells. A, In response to DNA damage, p53 can directly
repress the transcription of several master regulators of mES cells. p53 also induces the transcription of several Wnt ligand genes, whose protein
products are secreted from the stressed mES cells to act on neighboring cells in a paracrine manner. Interestingly, p53 up-regulates
differentiation-associated genes in ES cells, suggesting that p53 signaling connects to the developmental circuitry in ES cells upon DNA damage.
The cellular outcomes of p53 signaling in somatic cells are shown as a comparison. The p53-dependent cell cycle arrest and senescence are
absent or have not been reported in mES cells. B, In human ES cells, p53-miR axis is induced by a differentiation signal, retinoic acid (RA). p53
activates miR-34a and miR-145, which in turn repress Oct4, Sox2, Lin28a, and Klf4. p53 also induces the expression of miR-34a, b, and c in mouse
somatic cells upon the introduction of reprogramming factors. These miRs repress Sox2, Nanog, and nMyc, the reprogramming factors.
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that p53 activates enhancer RNAs (eRNAs) to up-regulate
transcription [65]. Therefore, it is reasonable to speculate
that p53 could interfere with the expression of eRNA to
repress transcription. Because enhancers normally drive
the cell type-specific gene transcription, it is possible thatp53 may repress the transcription of cell type specific
genes [66]. In summary, p53 is connected to the devel-
opmental gene network and is able to regulate the net-
work during developmental stresses, suggesting that
p53 may act as a surveillance system to ensure normal
development.
Shin et al. Cell & Bioscience 2013, 3:42 Page 6 of 10
http://www.cellandbioscience.com/content/3/1/42p53 regulates miRNAs in human ES cells and during
reprogramming of somatic cells
In human ES (hES) cells, p53 plays important roles in
regulating their differentiation and apoptosis (Figure 2B)
[53,67]. p53 can elicit cell cycle arrest in hES cells but
not in mES cells [54,59,68,69]. The difference may result
from the fact that hES cells are developmentally similar
to mouse epiblast cells (around 5.5 day of the embryo)
and mES cells are from 3.5-d blastocysts [70,71]. p53
promotes spontaneous apoptosis and differentiation of
hES cells [53]. Upon retinoic acid (RA)-induced differen-
tiation, p53 is activated and post-translationally modified
[67]. The activated p53 then induces the transcription of
miR-34a and miR-145, which can target the master regu-
lators of ES cells, such as Oct4, Sox2, Klf4, and Lin28a
[67]. A similar mode of action of p53 is also observed in
the reprogramming of mouse MEF cells into induced
pluripotency stem (iPS) cells (Figure 2B) [72]. There is
no doubt that p53-miR plays an important role in
repressing the master regulators of ES cells. Notably, the
repression of the master regulators by the p53-miR axis
occurs 24 hours after the RA treatment, suggesting that
it is a slower process than p53-mediated interference of
the enhancer activity in response to DNA damage, which
occurs within 8 hours [59]. Therefore, p53 may employ
multiple mechanisms to ensure the complete silencing
of these master regulators. Another possibility is that 53
may behave differently in human and mouse ES cells
since these two cell types represent two distinct develop-
mental stages [70,71]. Future studies need to address the
relative contribution of and relationship between the
p53-miR axis and interference of enhancer activity in
p53-mediated repression.
Is the developmental role of p53 associated with
the tumor suppressive function of p53?
The tumor suppressor p53 elicits many cellular functions
after various stresses, such as DNA damage, hypoxia, virus
infection, and unfolded protein shock. However, the con-
nection between the cellular function and the tumor sup-
pressive function is still unclear despite more than
30 years of study. Cell cycle arrest (reversible), senescence
(irreversible cell cycle arrest), and apoptosis all have been
shown to participate in tumorigenesis, suggesting that
they may contribute to the tumor suppressive function of
p53 [73]. Cdkn1a (also called p21 or Waf1), one of the
downstream targets of p53, regulates cell cycle arrest and
senescence [74]. Bbc3 (also called Puma) is required for
p53-dependent apoptosis [75]. However, both Cdkn1a and
Bbc3 are dispensable for the tumor suppressive function
of p53, and they are not frequently mutated in human
cancers, suggesting that other un-identified mechanisms
are also involved [74-76]. One of the possibilities is that all
the p53-mediated cellular functions are playing redundantroles during tumor suppression. The disruption of each of
these cellular functions individually does not phenocopy
the loss of p53 [41]. Another possibility is that we have
not found the right p53 downstream targets that mediate
the tumor suppressive function of p53. For example,
an elegant study using a mouse model harboring a
transcription-dead p53 mutant, p53 (25,26,53,54), showed
that the transcriptional activity of p53 is absolutely re-
quired for its tumor suppressive function [76]. Interest-
ingly, another p53 mutant, p53(25,26), cannot induce
genes involved in acute DNA damage response while still
maintaining the tumor suppressive function. These results
show that the acute DNA damage associated genes cannot
explain the tumor suppressive function of p53. Another
possibility is that other under-appreciated functions, such
as the metabolic or developmental role, of p53 are related
to the tumor suppression by p53 [77]. The metabolic
function of p53 has attracted much attention recently be-
cause even a p53 mutant that is defective in cell cycle ar-
rest, apoptosis, and senescence still has tumor suppressive
function [77,78]. Notably, this same p53 “super” mutant
still maintains its function in regulating the metabolic
pathway, suggesting that the metabolic pathway might be
one of the underlying pathways responsible for the tumor
suppressive function of p53. Thus far, the developmental
role of p53 has not been formally linked to its tumor sup-
pressive function. Development, by classical definition, is
the time between zygote and birth, while most cancers,
except for certain pediatric cancers, originate from som-
atic tissues. But the signaling pathways utilized by devel-
opment, such as the Wnt, Notch, and TGF beta signaling,
could be re-wired into a cancer program. Future efforts
should be put into the investigation of the normal devel-
opmental roles of p53 and compare them to those in can-
cer cells. Systematic analyses show that p53-regulated
genes in ES cells are playing a role in breast cancer and
prostate cancer, suggesting that the role of p53 in ES cells
may shed light on its tumor suppressive function [79,80].
One typical example demonstrating the relationship be-
tween the developmental role and tumor suppressive func-
tion of p53 is the functional interaction between Brca1 and
p53 (Figure 1C). In development, a hypomorphic Brca1
mutant (Brca1Δ11/Δ11) is not compatible with life. Crossing
Brca1Δ11/Δ11 mice with p53 heterozygous or null mice
completely rescue the embryonic lethality of Brca1Δ11/Δ11
(Figure 1C) [24]. However, most p53+/-;Brca1Δ11/Δ11
female mice develop mammary tumors in their adult-
hood (within 6-12 months). This example shows that
the failure of p53 signaling during development could
also lead to tumorigenesis in the adulthood. As de-
scribed above, p53 loss partially rescued the dys-
regulation of other genes, such as Brca2 and Rad51,
suggesting that the complete loss of these genes also acti-
vates p53-independent pathways to cause embryonic
Shin et al. Cell & Bioscience 2013, 3:42 Page 7 of 10
http://www.cellandbioscience.com/content/3/1/42lethality. Further studies are required to determine
whether the same scenario exists for other genes or in
human development.
Models of p53 in development
There are at least two non-exclusive models for p53 in
development (Figure 3). The first model, named the
“constitutive” model, states that p53 has a constitutive
or active role in regulating the developmentally essentialp53
Developm
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(partially loFunctional redundant 
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Figure 3 Models of the developmental roles of p53. A, A “constitutive”
and p73, are constitutively regulating the developmentally essential genes.
players. B, A “passive” model: p53 signaling is activated by stochastic dys-re
p53 is inactive but can be activated in response to developmental stresses
stochastic nature of developmental stresses results in the low penetrance ogenes (Figure 3A). Other functionally redundant players,
e.g. p63 and p73, could partially compensate for the loss
of p53. Therefore, the loss of p53 only causes a low pene-
trance of developmental defects, such as rare exencephaly.
This “constitutive” model is relatively straightforward and
separates the function of p53 in acute stress response from
its developmental roles. This model is also supported by
studies in Xenopus, in which the loss of p53 completely
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in low penetrance of developmental defects. The sec-
ond model, called the “passive” model, combines the
stress responsive function of p53 with its developmen-
tal roles (Figure 3B). In this “passive” model, p53-
mediated stress responsive signaling will be activated
only if the developmental process is dys-regulated.
Normally, the dys-regulation of developmentally essen-
tial genes happens stochastically in embryos. It is this
stochastic feature of developmental dys-regulation that
causes the incomplete penetrance of developmental
defects in p53 knockout mice. Although p53 activation
could be detrimental to an individual embryo, it is
beneficial to the whole population by ensuring that
only normally developed embryos survive. We note
that the two models proposed in this review are by no
means comprehensive but serving as a framework for
future modifications.
Perspective
ES cells, as an excellent model for early development,
have provided many novel insights into the developmen-
tal roles of p53. However, ES cells only represent a snap-
shot of development. p53 regulates very different sets of
genes in different cell types [81]. Caution needs to be
taken when extrapolating the results in ES cells into
other developmental stages. The epigenetic landscapes
in different cell types will shape the p53 signaling. For
example, the p53-Wnt axis is tightly associated with ES
cells but not in MEF and neural progenitor cells. In
addition, how the p53-miR axis connects to the develop-
mental program is largely unknown. More studies are
needed to put the piece of p53 in development into the
big puzzle of the tumor suppressive function of p53 in
order to more effectively design therapeutic, preventive
and diagnostic strategies to combat cancer. As the ap-
proaches of systems biology and genomics become in-
creasingly available, they will provide more insights into
the developmental roles of p53 and the relationship be-
tween development and cancer.
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